Canada markets close in 2 hours 42 minutes

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3100-0.0299 (-8.80%)
As of 12:59PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.3399
Open0.3225
BidN/A x N/A
AskN/A x N/A
Day's Range0.3000 - 0.3328
52 Week Range0.0600 - 0.9700
Volume49,587
Avg. Volume90,694
Market Cap98.518M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1470
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

    LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the “Board”). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier ha

  • GlobeNewswire

    Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder

    FDA discussions pave pathway for U.S. clinical trial preparationsLONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies today confirms, following positive discussions with the U.S. Food and Drug Administration (the “FDA”), that preparations are now underway for the U.S. component of its Phase IIb clinical trial for its lead candidate, SPL026, a N,N-dimethyltr

  • GlobeNewswire

    Small Pharma to Attend Upcoming Healthcare Conferences in November 2021

    LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its attendance at the LSX Inv€$tival ShowcaseTM conference and the Jefferies London Healthcare Conference during the month of November. Details of the conferences are as follows: LSX Inv€$tival ShowcaseTM conferenceSmall Pharma is participating in the LSX Inv€$tival ShowcaseTM conf